Description
Tri-Itra 200 SB (Itraconazole B.P. 200mg) capsules are formulated with cutting-edge SUBA (Super Bio-Available) technology, which significantly improves the absorption and bioavailability of poorly soluble drugs. SUBA technology works by creating a solid dispersion of itraconazole within a polymer matrix, ensuring that the drug dissolves more efficiently than in its normal crystalline form. This enhanced formulation offers therapeutic benefits equivalent to a conventional 200 mg itraconazole capsule.
Itraconazole, a potent antifungal agent, is well known for its broad-spectrum activity against a range of fungal infections, including dermatophytosis, onychomycosis, and systemic mycoses. By utilizing SUBA technology, Tri-Itra 200 SB ensures better patient outcomes with higher compliance and superior efficacy compared to standard itraconazole and fluconazole treatments.
Key Features:
- Advanced SUBA technology for enhanced drug bioavailability.
- Equivalent to conventional 200 mg itraconazole capsules.
- Effective against a wide range of fungal infections.
- Improved clinical efficacy and patient compliance over fluconazole.
Indications:
- Onychomycosis (fungal nail infections)
- Dermatophytosis (skin fungal infections)
- Systemic fungal infections
Tri-Itra 200 SB is ideal for patients requiring a reliable, broad-spectrum antifungal solution with improved absorption, faster therapeutic results, and better tolerance compared to conventional formulations.